• Covalent Data

  Led · Series A · Apr 2016

  Covalent Data offers an innovation intelligence platform that collects content about the global innovation landscape. The service leverages disparate sets of public and private data to trace the journey of invention from the earliest stages of research through commercialization. Its tools enable participants across the innovation ecosystem to efficiently track trends, analyze opportunities, and connect with one another. The platform allows researchers to showcase expertise, institutions to market assets, foundations to evaluate grant applicants, and licensing professionals to discover technologies. The company is led by Tim Oliver (CEO) and Will Butler (CTO). Financially, Covalent completed a $1.2M Series A-1 and has raised $4.8M to date; it intends to use the new funds to focus on the output of individual research scientists.

• TriSalus Life Sciences

  Participated · Series C · Dec 2015

  TriSalus Life Sciences develops a drug delivery platform that includes devices using its proprietary Pressure-Enabled Drug Delivery (PEDD) approach and a clinical-stage investigational immunotherapy, nelitolimod. The company has two FDA-cleared devices: the TriNav® Infusion System for hepatic arterial infusion to liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is designed to modulate pressure and flow to deliver more therapeutic to tumors while reducing undesired delivery to normal tissue. Nelitolimod is intended to treat the immunosuppressive tumor environment that can limit current immunotherapies, and patient data from Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects. TriSalus plans to study nelitolimod delivered by PEDD across several indications where TLR9 is expressed and mechanical delivery barriers exist. The company works in partnership with leading cancer centers to advance its technology and clinical programs. Following the recent financing, TriSalus expects its cash runway to extend through 2025. Surefire Medical develops, manufactures and markets targeted delivery devices for the Interventional Oncology market centered on its Surefire Infusion System (SIS), a microcatheter with an expandable tip that increases infusion pressure and blocks backflow. The SIS is designed to deliver significantly more therapy into tumors while protecting healthy tissue. Clinical data cited include a randomized trial showing 68% improved tumor uptake and 58% decreased non-target delivery, a registry reporting 68% complete tumor response and 92% objective response, and a retrospective comparison showing a 79% versus 37% objective response for HCC. The company plans to use new financing to expand sales and marketing in the U.S. and Europe, initiate sales and clinical trials in China, and complete the 170-patient randomized QED trial (NCT02748161). Surefire is also pursuing opportunities in the $66B immunotherapy market, targeting site-specific delivery to solid tumors. The company is based in Westminster, Colo. Surefire Medical develops infusion and direct-to-tumor delivery systems for the interventional radiology and interventional oncology markets. Its flagship device, Surefire Precision, is specifically designed for targeted delivery in the treatment of primary liver cancer (HCC). The company is commercial stage and has received regulatory approvals in the U.S., Europe, Canada, Australia, New Zealand, Taiwan, Mexico and Brazil. Founded in 2009 and led by President and CEO James Chomas, the company is based in Westminster, Colorado. Surefire plans to use the new funding to support the global launch of Surefire Precision. It closed a $15M Series C in February 2015 to fund those commercial expansion efforts. Surefire Medical develops infusion systems designed to deliver embolic agents through a microcatheter using an expandable tip that collapses in forward flow and expands to the vessel wall in reverse flow. Its product family includes the Surefire Infusion System (ST, LT, mT) and specialty catheters. The company is commercial-stage and its devices have received regulatory approvals in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. Surefire intends to use the financing to expand product development, clinical trials, operations and marketing. The company was founded in 2009 and is led by CEO Jim Chomas. It is based in Westminster, Colorado.

• Kapost

  Participated · Equity · May 2015

  Kapost offers a Marketing Content Engine that helps marketers plan, execute, distribute and optimize the entire B2B content lifecycle. Its platform combines calendaring, collaboration tools, workflows, analytics, streamlined distribution and a broad set of integrations to standardize content operations. The company also provides services and packages to help customers build integrated content frameworks and operationalize content at scale. Kapost reports more than 120 customers, including Dell, IBM, Zurich and LinkedIn, spanning Fortune 100s to fast-growth businesses. The company announced $10.25 million in new funding to accelerate growth and to 'supercharge' its software and services, according to CEO and co-founder Toby Murdock. The funding is intended to help expand product capabilities and support customers as content becomes central to marketing operations. Kapost is a Boulder, CO-based content marketing software platform co-founded by CEO Toby Murdock and CTO Nader Akhnoukh. The platform helps marketing teams structure every step of the content process, including planning and organization, production, distribution and performance measurement. Its solution offers tools to manage social posts, blog posts, eBooks, videos and other content types and includes an analytics suite. Kapost serves more than 100 customers, including Intel, AT&T, Oracle, Allstate, General Mills and Lenovo. The company plans to use the new funds to scale the organization. On July 18, 2013 Kapost raised $5.6m in funding from new and existing investors. Kapost builds a newsroom platform that lets publishers manage, assign, edit and publish content from an army of contributors while integrating with publishers' existing CMS workflows. The product is early stage and currently includes core functionality such as assigning stories to authors. More advanced features—specifically distributing payments to contributors and editorial calendars—are still in development. The company previously operated as Grogger (a crowdsourced CMS) and pivoted to Kapost to avoid requiring publishers to replace their CMS. Kapost participated in the TechStars Boulder program. CEO Toby Murdock is cited describing the product and its target customer base.

• Nutrinsic

  Participated · Equity · Aug 2014

  Nutrinsic produces ProFloc™, a high-quality protein ingredient for animal nutrition made using a patented process that upcycles nutrients lost in food and beverage plant wastewater treatment. The company intends to use new funding to continue to grow its sustainable protein business. It is building its first U.S. production facility in Trenton, Ohio, slated to come online by year-end 2014. A facility in China has been operational for several months and is co-owned by Nutrinsic and other partners in a joint venture. Leo Gingras serves as Chief Executive Officer. The company is based in Glendale, Colorado.

• Collective IP

  Led · Series A · Nov 2013

  Collective IP offers an innovation intelligence platform consisting of a search engine and a marketplace that connects business development with technology transfer and corporate licensing professionals. The platform organizes technologies emerging from universities, companies and research institutes to surface valuable assets. Led by Founder and Chief Operating Officer Adam Rubenstein, the company aims to help users identify and transact around innovations. New features in development include enhanced tools to identify, analyze, manage and market new innovations and the people behind them. Financially, the company has raised a total of $3.6M to date and completed a $2.5M Series A to continue building and innovating the product.

No current team members are available.